Myriad Genetics ex-Chief Commercial Officer Brian Donnelly exits company under separation agreement

• Myriad Genetics disclosed the departure of Chief Commercial Officer Brian Donnelly, effective Sept. 16, 2026.
• Donnelly’s employment ended at the close of business on Sept. 21, 2026, under a separation agreement dated Oct. 6, 2026.
• The agreement includes accelerated vesting for certain time-based equity awards over a two-year period from the separation date.
• Performance-based equity awards remain outstanding, with potential vesting tied to results achieved within two years of the separation date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000899923-26-000084), on October 09, 2026, and is solely responsible for the information contained therein.